New Interventions Address Sexual Health after Ovarian Cancer Treatment

Ovarian cancer often goes undetected before it reaches more invasive stages, but there is one aspect of the disease that frequently remains ignored even after diagnosis: Its impact upon a patient’s sexual health and function. Now, as research and treatment advances are allowing more women to live longer and healthier with ovarian cancer, Dana-Farber is … Read more

Drug Prolongs Remissions in Some Relapsed Ovarian Cancers

Ed. note: Niraparib (Zejula) was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2017, as a maintenance therapy for women with ovarian, fallopian tube, or primary peritoneal cancer. This post was originally published on Oct. 21, 2016. For women with relapsed ovarian cancer that responds to platinum-based chemotherapy, a drug that hampers … Read more

Treatments for Ovarian Cancer: Finding Your Path [Infographic]

Ovarian cancer is a complex disease. Cell types, stages, and genetics play an important role for patients and their doctors as they decide which direction to take. Fortunately, patients today have many treatment options and new advances on the horizon. Physician-scientists at the Susan F. Smith Center for Women’s Cancers are leading the way in … Read more

Improving Sexual Health for Ovarian Cancer Patients

Treatment for ovarian cancer often comes with sexual side effects. Although curing the cancer is the main goal for many patients and their doctors, Sharon Bober, PhD, director of Dana-Farber’s Sexual Health Program, is focused on preserving a patient’s quality of life – including her sexual satisfaction. Bober, with co-investigators Alexi Wright, MD, MPH, a … Read more

Clinical Trial Helps Betsy Brauser Live with Ovarian Cancer

As researchers and clinicians in the Susan F. Smith Center for Women’s Cancers at Dana-Farber continue studying the benefits of a two-drug combination in slowing progression of recurrent ovarian cancer, one patient is as a beacon of hope for her caregivers – and for others facing the disease. Betsy Brauser, treated with standard chemotherapy near … Read more

Cancer Conversations Podcast – Episode #3: The Latest in Ovarian Cancer Treatment and Research

Although ovarian cancer can sometimes be difficult to treat, researchers and physicians are finding new ways to approach the disease, making way for promising alternatives to the traditional chemotherapy treatments. In this Cancer Conversations podcast episode, Ursula Matulonis, MD, Panos Konstantinopoulos, MD, PhD, and Susana Campos, MD, MPH, from the Gynecologic Oncology Program at the Susan … Read more

Can Two Ovarian Cancer Drugs Succeed Where Others Have Failed?

When Donna Gregory’s ovarian cancer came back for the third time, she began looking for alternatives to chemotherapy. She’d been diagnosed with stage III ovarian cancer in 2003, at age 58. After having surgery to remove her tumors, she tried platinum-based chemotherapy, but her cancer did not respond. Several more chemotherapy drugs worked, but only … Read more

Promising Research Developments Stir Hopes for Melanoma, Lung, Breast and Ovarian Cancer

The growing excitement about the potential of immunotherapy treatments for cancer continued at the 2015 meeting of the American Association for Cancer Research (AACR), one of the largest cancer research meetings of the year. Several Dana-Farber investigators presented encouraging results of immunotherapy for melanoma, lung cancer, and breast cancer. F. Stephen Hodi, MD, and Leena … Read more

Angelina Jolie Puts Spotlight on Genetic Testing and Ovarian Cancer Risk

Once again Angelina Jolie is making headlines after penning another op-ed in The New York Times. The actress shared she has undergone more cancer preventive surgery – this time prophylactic salpingo-oophorectomy, a procedure to have her ovaries and fallopian tubes removed. Two years ago, she wrote about her decision to have a prophylactic double mastectomy, … Read more